• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[食管癌多模式治疗中食管切除术的时机:新辅助治疗与手术之间的时间间隔对结局和反应的影响]

[Timing of esophagectomy in multimodal therapy of esophageal cancer: Impact of time interval between neoadjuvant therapy and surgery on outcome and response].

作者信息

Müller A-K, Lenschow C, Palmes D, Senninger N, Hummel R, Lindner K

机构信息

Klinik für Allgemein- und Viszeralchirurgie, Universitätsklinikum Münster, Waldeyerstr. 1, 48149, Münster, Deutschland.

出版信息

Chirurg. 2015 Sep;86(9):874-80. doi: 10.1007/s00104-014-2916-6.

DOI:10.1007/s00104-014-2916-6
PMID:25662991
Abstract

BACKGROUND

Neoadjuvant radiochemotherapy [n(R)CT] has become the standard of care in the multimodal therapy concept for patients with locally advanced esophageal cancer; however, optimal timing of surgery is not clearly defined.

OBJECTIVES

The study analyzed whether the length of the interval between completion of n(R)CT and surgery can affect the postoperative outcome, tumor response and long-term survival.

MATERIAL AND METHODS

A total of 106 patients with adenocarcinoma and squamous cell carcinoma of the esophagus, treated between 2006 and 2013, were included in this study. On the basis of the median time interval to surgery, patients were divided into two groups [group A ≤ 40 days (n = 54) and group B > 40 days (n = 52)] and compared concerning demographic data, preoperative risk scores, morbidity, outcome, tumor response and long-term survival.

RESULTS

The groups were comparable in terms of demographics, preoperative condition of the patients, complications and outcome; however, group A showed a trend towards a higher mortality risk as preoperatively assessed by the physiological and operative severity score for the enumeration of mortality and morbidity in esophagogastric surgery patients (O-POSSUM) (p = 0.064) and group B showed a trend towards a higher rate of complete responders (p = 0.097).

CONCLUSION

Concerning perioperative morbidity and mortality, delayed surgery after n(R)CT showed no benefit for the patient's outcome; however, the rate of complete tumor response was higher in patients with a time interval of more than 40 days, although this did not influence long-term survival or recurrence rates.

摘要

背景

新辅助放化疗[n(R)CT]已成为局部晚期食管癌患者多模式治疗理念中的标准治疗方法;然而,手术的最佳时机尚未明确界定。

目的

本研究分析了n(R)CT结束至手术之间的间隔时间长短是否会影响术后结局、肿瘤反应和长期生存。

材料与方法

本研究纳入了2006年至2013年间接受治疗的106例食管腺癌和鳞状细胞癌患者。根据至手术的中位时间间隔,将患者分为两组[A组≤40天(n = 54)和B组>40天(n = 52)],并比较了人口统计学数据、术前风险评分、发病率、结局、肿瘤反应和长期生存情况。

结果

两组在人口统计学、患者术前状况、并发症和结局方面具有可比性;然而,A组经食管胃手术患者死亡率和发病率枚举的生理和手术严重程度评分(O-POSSUM)术前评估显示有更高死亡风险的趋势(p = 0.064),B组显示有更高完全缓解率的趋势(p = 0.097)。

结论

关于围手术期发病率和死亡率,n(R)CT后延迟手术对患者结局无益处;然而,间隔时间超过40天的患者肿瘤完全缓解率更高,尽管这并未影响长期生存或复发率。

相似文献

1
[Timing of esophagectomy in multimodal therapy of esophageal cancer: Impact of time interval between neoadjuvant therapy and surgery on outcome and response].[食管癌多模式治疗中食管切除术的时机:新辅助治疗与手术之间的时间间隔对结局和反应的影响]
Chirurg. 2015 Sep;86(9):874-80. doi: 10.1007/s00104-014-2916-6.
2
Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.基于食管癌新辅助治疗病理反应的长期生存情况
J Surg Res. 2017 Aug;216:65-72. doi: 10.1016/j.jss.2017.03.022. Epub 2017 Mar 31.
3
Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.新辅助治疗对 T3N0M0 期食管鳞癌患者生存获益的影响:一项回顾性多中心欧洲研究结果。
Ann Surg. 2017 Nov;266(5):805-813. doi: 10.1097/SLA.0000000000002402.
4
[Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients].新辅助放化疗后手术治疗食管癌的长期疗效:一项针对102例患者的单机构回顾性研究
Cancer Radiother. 2015 Aug;19(5):322-30. doi: 10.1016/j.canrad.2015.04.004. Epub 2015 Jul 26.
5
Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.分析因食管癌而接受新辅助治疗后择期手术但最终未行食管癌切除术的患者。
World J Surg Oncol. 2019 May 27;17(1):89. doi: 10.1186/s12957-019-1630-8.
6
Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.新辅助放化疗与食管或食管胃交界癌手术的时间间隔:一项全国性研究。
Eur J Cancer. 2018 Mar;91:76-85. doi: 10.1016/j.ejca.2017.12.009. Epub 2018 Jan 30.
7
Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.新辅助治疗后远端食管腺癌的食管切除术时机
Ann Thorac Surg. 2016 Mar;101(3):1123-30. doi: 10.1016/j.athoracsur.2015.09.044. Epub 2015 Dec 1.
8
Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.局部晚期食管癌的淋巴结转移:新辅助治疗如何改变其频率和分布。
Ann Surg Oncol. 2011 Dec;18(13):3743-54. doi: 10.1245/s10434-011-1753-9. Epub 2011 May 10.
9
Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.局部晚期食管腺癌的多模态治疗:我们应该选择哪种方案?105 例患者围手术期化疗与新辅助放化疗的疗效分析。
J Surg Oncol. 2014 Mar;109(3):287-93. doi: 10.1002/jso.23498. Epub 2013 Nov 26.
10
Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.单机构对食管癌腺癌术前与根治性放化疗的回顾性比较
Ann Surg Oncol. 2014 Nov;21(12):3744-50. doi: 10.1245/s10434-014-3795-2. Epub 2014 May 23.

引用本文的文献

1
Economic Burden of Endoscopic Vacuum Therapy Compared to Alternative Therapy Methods in Patients with Anastomotic Leakage After Esophagectomy.与食管癌切除术后吻合口漏患者的替代治疗方法相比,内镜下真空治疗的经济负担
J Gastrointest Surg. 2021 Oct;25(10):2447-2454. doi: 10.1007/s11605-021-04955-w. Epub 2021 Feb 24.
2
Timing of surgery after neoadjuvant chemoradiotherapy affects oncologic outcomes in patients with esophageal cancer.新辅助放化疗后手术时机对食管癌患者的肿瘤学结局有影响。
World J Gastrointest Oncol. 2020 Jun 15;12(6):687-698. doi: 10.4251/wjgo.v12.i6.687.
3
Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study.

本文引用的文献

1
Does neoadjuvant therapy for esophageal cancer increase postoperative morbidity or mortality?食管癌新辅助治疗会增加术后发病率或死亡率吗?
Dis Esophagus. 2015 Oct;28(7):644-51. doi: 10.1111/dote.12251. Epub 2014 Jul 24.
2
Impact of preoperative risk factors on morbidity after esophagectomy: is there room for improvement?术前危险因素对食管癌切除术后发病率的影响:是否有改进空间?
World J Surg. 2014 Nov;38(11):2882-90. doi: 10.1007/s00268-014-2686-9.
3
Postoperative complications do not affect long-term outcome in esophageal cancer patients.
新辅助放化疗与手术时间间隔与食管和胃食管交界处癌完全组织学肿瘤反应的关系:一项全国性队列研究。
Dis Esophagus. 2020 May 15;33(5). doi: 10.1093/dote/doz078.
4
A case of IV degree on acute radiation dermatitis in China.中国一例急性放射性皮炎IV度病例。
Int J Surg Case Rep. 2017;32:19-21. doi: 10.1016/j.ijscr.2017.01.068. Epub 2017 Feb 2.
术后并发症不影响食管癌患者的长期预后。
World J Surg. 2014 Oct;38(10):2652-61. doi: 10.1007/s00268-014-2590-3.
4
Does timing of surgical procedure after neoadjuvant chemoradiation affect outcomes in esophageal cancer?新辅助放化疗后手术时机是否影响食管癌的治疗效果?
Ann Thorac Surg. 2014 Apr;97(4):1181-9. doi: 10.1016/j.athoracsur.2013.12.026. Epub 2014 Feb 14.
5
The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma.新辅助治疗食管腺癌后肿瘤组织病理存活状态对长期生存和复发率的影响。
Ann Surg. 2013 Sep;258(3):500-7. doi: 10.1097/SLA.0b013e3182a196f4.
6
Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?新辅助放化疗与手术治疗食管鳞癌的时间间隔:手术延迟是否影响预后?
Ann Surg Oncol. 2013 Dec;20(13):4245-51. doi: 10.1245/s10434-013-3139-7.
7
Esophagectomy after chemoradiation: who and when to operate.放化疗后食管癌切除术:谁和何时手术。
Semin Thorac Cardiovasc Surg. 2012 Winter;24(4):288-93. doi: 10.1053/j.semtcvs.2012.10.005.
8
Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor.预测食管胃腺癌患者预后和复发的因素及肿瘤残留小于 10%的组织病理学反应。
Langenbecks Arch Surg. 2013 Feb;398(2):239-49. doi: 10.1007/s00423-012-1039-0. Epub 2012 Dec 27.
9
What is the optimal interval between chemoradiation and esophagectomy?放化疗与食管癌切除术的最佳间隔时间是多久?
Semin Thorac Cardiovasc Surg. 2012 Summer;24(2):87-9. doi: 10.1053/j.semtcvs.2012.06.001.
10
Does the timing of esophagectomy after chemoradiation affect outcome?放化疗后行食管切除术的时机是否影响疗效?
Ann Thorac Surg. 2012 Jan;93(1):207-12; discussion 212-3. doi: 10.1016/j.athoracsur.2011.05.021. Epub 2011 Oct 1.